Home

CATHERINE M VACZY

CIK 1177176 · EVP GC Chief Strategy Officer · last filed 2023-04-24

CATHERINE M VACZY is an EVP GC Chief Strategy Officer who has filed 29 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider bought $21.5K of GNPX on Apr 24, 2023. Across all open-market trades the lifetime net is +$21.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $48 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$48

Companies

4

Total Filings

29

Lifetime Open-Market Net

$21.5K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GNPX EVP GC Chief Strategy Officer 6 $8.03 $48 $21.5K 4 2023-04-24
LISATA THERAPEUTICS, INC. (NBS) Delisted General Counsel 71,234 — — $0 9 2015-04-14
LISATA THERAPEUTICS, INC. (NBS.WS) Delisted VP and General Counsel 345,362 — — $0 14 2012-06-27
LISATA THERAPEUTICS, INC. (NBS.U) Delisted VP and General Counsel 123,772 — — $0 1 2007-10-01

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-04-24 GNPX Buy (P) +20,000 $21.5K EDGAR
2023-02-22 GNPX Grant (A) +245,000 $0 EDGAR
2022-02-08 GNPX Grant (A) — $0 EDGAR
2021-03-23 GNPX Grant (A) — $0 EDGAR
2015-04-14 LISATA THERAPEUTICS, INC. (NBS) Delisted Grant (A) +3,971 $0 EDGAR
2015-02-06 LISATA THERAPEUTICS, INC. (NBS) Delisted Mixed +17,904 -$42.8K EDGAR
2015-01-02 LISATA THERAPEUTICS, INC. (NBS) Delisted Grant (A) +962 $3.1K EDGAR
2014-08-01 LISATA THERAPEUTICS, INC. (NBS) Delisted Grant (A) +11,756 $0 EDGAR
2014-07-01 LISATA THERAPEUTICS, INC. (NBS) Delisted Grant (A) +556 $3.1K EDGAR
2014-01-03 LISATA THERAPEUTICS, INC. (NBS) Delisted Grant (A) +598 $2.9K EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.